Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Trial Details

NCT ID
NCT05952024
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Acalabrutinib
  • Rituximab
Locations (sample)
  • Berkeley, California, United States|37.87159,-122.27275
  • La Jolla, California, United States|32.84727,-117.2742
  • Orange, California, United States|33.78779,-117.85311
  • Stamford, Connecticut, United States|41.05343,-73.53873
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • ≥ 80 years of age at the time of screening, or
  • ≥ 65 to 79 years of age at the time of screening and considered ineligible for chemoimmunotherapy
  • Histologically documented DLBCL
  • No prior treatment for DLBCL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →